Childhood cancers trials in Canada

In Canada 154 Also abroad 2459

154 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Where
Calgary, Toronto
People
115 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT03394365 · EU 2024-516622-57-00
Phase 1Taking people
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Where
Calgary, Montreal, Ottawa, Toronto
Age
15 years and over
People
30
Run by
Canadian Cancer Trials Group
See details and how to joinNCT07297667
Phase 1/2Taking people
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Where
Toronto, Vancouver
Age
12 years and over
People
83 worldwide
Run by
AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00
Phase 2Taking people
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Where
Calgary, Edmonton, Montreal, Sherbrooke, Toronto
Age
Up to 21 years
People
50 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06064097
Phase 1Taking people
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Where
Calgary, Ottawa, Toronto, Vancouver
Age
1 year and over
People
24
Run by
British Columbia Cancer Agency
See details and how to joinNCT06208735
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Montreal, Toronto
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Toronto
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Toronto
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
No phaseTaking people
CfDNA in Hereditary And High-risk Malignancies 2
Where
Halifax, Montreal, St. John's, Toronto, Vancouver
Age
Up to 90 years
People
1,000
Run by
University Health Network, Toronto
See details and how to joinNCT06726642
Phase 1/2Taking people
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Where
Montreal
Age
Up to 30 years
People
104 worldwide
Run by
Milton S. Hershey Medical Center
See details and how to joinNCT06541262
Phase 1/2Taking people
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Where
Québec, Toronto, Victoria
People
64 worldwide
Run by
RayzeBio, Inc.
See details and how to joinNCT06590857
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Toronto
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Calgary, Toronto
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00
No phaseTaking people
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
Where
Toronto
Age
Up to 21 years
People
5,000 worldwide
Run by
Massachusetts General Hospital
See details and how to joinNCT01696721
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Where
Montreal, Toronto
People
64 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602777
Phase 1/2Taking people
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Where
Calgary, Edmonton, Montreal, Ottawa
Age
Up to 25 years
People
75 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00
No phaseNot yet taking people in Canada
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
Where
London
People
25
Run by
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
See details and how to joinNCT07510906
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Edmonton, Toronto
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 3Taking people
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
Where
Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
7 years to 21 years
People
140 worldwide
Run by
Donald Mabbott
See details and how to joinNCT05230758
Phase 2Taking people
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Where
Calgary, Edmonton, Halifax, Hamilton, Montreal, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
3 years to 29 years
People
160 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT04684368
Phase 2Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Where
Montreal, Ottawa, Québec, Toronto, Vancouver
People
1,500 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00
Phase 3Taking people
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Where
Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
6 months to 21 years
People
1,400 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT04293562
Phase 3Taking people
Study of Out of Specification for Tisagenlecleucel
Where
Hamilton, Montreal, Ottawa, Québec, Toronto
Age
0 years to 100 years
People
200 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04094311
No phaseTaking people
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
Where
Montreal, Toronto
Age
Up to 17 years
People
1,600 worldwide
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06651580
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Edmonton, London, Montreal, Toronto
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00